The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Risks in new drug development: Approval success rates for investigational drugs
Abstract
Clinical Pharmacology & Therapeutics (2001) 69, 297–307; doi: 10.1067/mcp.2001.115446
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
Self-citationSuccess rates for new drugs entering clinical testing in the United States
DiMasi, J. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90066-7 · Cited by 184
Self-citationDiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1995) · PharmacoEconomics · doi:10.2165/00019053-199507020-00007 · Cited by 169
Self-citationDiMasi, J. A. (2000) · Drug Information Journal · doi:10.1177/009286150003400425 · Cited by 78
Self-citationR&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
DiMasi, J. A., Grabowski, H. G., & Vernon, J. (1995) · International Journal of the Economics of Business · doi:10.1080/758519309 · Cited by 73
Self-citationNew drug development in the United States from 1963 to 1992
DiMasi, J. A., Seibring, M., & Lasagna, L. C. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.78 · Cited by 72
Self-citationNew drug development in the United States, 1963 through 1984
Mattison, N., Trimble, A. G., & Lasagna, L. C. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.35 · Cited by 53
Measuring the Pace of New Drug Development in the User Fee ERA
Kaitin, K. I., & DiMasi, J. A. (2000) · Drug Information Journal · doi:10.1177/009286150003400303 · Cited by 50
Self-citationThe New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era
Kaitin, K. I., & Healy, E. M. (2000) · Drug Information Journal · doi:10.1177/009286150003400101 · Cited by 45
Cited by
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Drug development for neglected diseases: a deficient market and a public-health policy failure
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09096-7 · Cited by 893
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Self-citationShuhendler, A. J., Pu, K., Cui, L., Uetrecht, J. P., & Rao, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2838 · Cited by 623
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
Self-citationKey factors in the rising cost of new drug discovery and development
Dickson, M., & Gagnon, J. P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1382 · Cited by 498
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479
Deconstructing the Drug Development Process: The New Face of Innovation
Kaitin, K. I. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.293 · Cited by 418
Economics of New Oncology Drug Development
DiMasi, J. A., & Grabowski, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0803 · Cited by 348
Self-citationEthiraj, S. K., & Levinthal, D. (2004) · Administrative Science Quarterly · doi:10.2307/4131441 · Cited by 339
Bergstr�m, M., Grahn�n, A., & L�ngstr�m, B. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0643-x · Cited by 311
Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances
Danzon, P. M., Nicholson, S., & Pereira, N. S. (2005) · Journal of Health Economics · doi:10.1016/j.jhealeco.2004.09.006 · Cited by 290
Changing R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
Predicting ADME properties in silico: methods and models
Butina, D., Segall, M. D., & Frankcombe, K. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02288-2 · Cited by 284
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
Lappin, G., & Garner, R. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1037 · Cited by 260
Clinical trial registration: transparency is the watchword
Sim, I., Chan, A.-W., Gülmezoglu, A. M., Evans, T., & Pang, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68708-4 · Cited by 165
Liposome imaging agents in personalized medicine
Petersen, A. L., Hansen, A. E., Gabizon, A., & Andresen, T. L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.003 · Cited by 164
Molecular imaging with SPECT as a tool for drug development
Gomes, C. M., Abrunhosa, A. J., Ramos, P., & Pauwels, E. K. J. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.015 · Cited by 100
Metadata
- Authors
- DiMasi, J. A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2001-05
- Volume
- 69
- Issue
- 5
- Pages
- 297-307
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2029342376
- Cited by
- 450
- References
- 16
- FWCI
- 43.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.